Long-term outcomes of autoimmune pancreatitis

Table 3 Development of cancer at or after autoimmune pancreatitis diagnosis

Ref.	Year	Follow-up period (mo)	Incident rate of PC	Incident rate of extrapancreatic cancer
Nishino et al[27]	2006	41	0.0% (0/12)	16.7% (2/12)
Takuma et al[50]	2011	40	0.0% (0/50)	NA
Yamamoto et al[51]	2012	37	0.0% (0/106)1	10.1% (11/106)1
Shiokawa et al[52]	2012	40	0.0% (0/108)	13.9% (15/108)
Hart et al[12]	2013	NA	0.7% (5/659)	7.0% (46/659)
Gupta et al[48]	2013	49	2.4% (2/84)	NA
Hart et al[49]	2014	43	0.9% (1/116)	9.5% (11/116)
Huggett et al[37]	2014	33	0.9% (1/115)2	7.0% (8/115)2
Hirano et al[47]	2014	73	2.1% (2/95)	11.5% (13/113)1
Ikeura et al[46]	2014	62	4.8% (3/63)	3.2% (2/63)
Shimizu et al[45]	2015	54	1.2% (1/84)	11.9% (8/84)
Buijs et al[24]	2015	75	0.0% (0/68)	11.8% (8/68)

¹Includes patients with systemic IgG4-related disease without autoimmune pancreatitis;

²Includes patients with IgG4-related sclerosing cholangitis. NA: Not available; PC: Pancreatic cancer.